Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP8 | P22894 | 1/20 | 0.48 |
| ▸ | SLC6A4 | P31645 | 14/20 | 0.45 |
| ▸ | ACACB | O00763 | 1/20 | 0.44 |
| ▸ | MAOA | P21397 | 1/20 | 0.44 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.44 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24129410 | 0.92 | MMP8 (0.51) | MMP8SLC6A4MAOASLC6A2SLC6A3 | |
| SCHEMBL19249372 | 0.84 | MMP8 (0.45) | MMP8SLC6A4ACACBALDH1A1TSHR | |
| SCHEMBL5326604 | 0.84 | MMP8 (0.53) | MMP8ACACBALDH1A1LMNATSHR | |
| SCHEMBL2050344 | 0.84 | MMP8 (0.53) | MMP8ACACBALDH1A1TSHR | |
| SCHEMBL9471326 | 0.83 | MMP8 (0.44) | MMP8SLC6A4MAOASLC6A2SLC6A3 | |
| SCHEMBL7696784 | 0.83 | ESR1 (0.51) | MMP8SLC6A2ALDH1A1 | |
| SCHEMBL901733 | 0.81 | EPHX2 (0.50) | MMP8ACACBKDM4EALDH1A1LMNA | |
| SCHEMBL2426124 | 0.81 | MMP8 (0.54) | MMP8ACACBALDH1A1LMNA | |
| SCHEMBL2429506 | 0.81 | PPARG (0.50) | MMP8KDM4EALDH1A1LMNA | |
| SCHEMBL3764833 | 0.81 | MMP8 (0.50) | MMP8ALDH1A1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230036933-A1 | HETEROCYCLIC INHIBITORS OF ENPP1 | VOLASTRA THERAPEUTICS, INC. (US) | 2023-02-02 | — | — | US | disclosed |
| WO-2021257614-A1 | HETEROCYCLIC INHIBITORS OF ENPP1 | VOLASTRA THERAPEUTICS, INC. (US) | 2021-12-23 | — | — | WO | disclosed |
| EP-1432720-A1 | O-PYRAZOLE GLUCOSIDE SGLT2 INHIBITORS AND METHOD OF USE | Bristol-Myers Squibb Company (US) | 2004-06-30 | — | — | EP | disclosed |
| US-20030087843-A1 | O-pyrazole glucoside SGLT2 inhibitors and method of use | BRISTOL-MYERS SQUIBB COMPANY | 2003-05-08 | — | — | US | disclosed |
| WO-2003020737-A1 | O-PYRAZOLE GLUCOSIDE SGLT2 INHIBITORS AND METHOD OF USE | BRISTOL-MYERS SQUIBB COMPANY (US) | 2003-03-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230036933-A1 | HETEROCYCLIC INHIBITORS OF ENPP1 | ENPP1, ENPP3, ENPP2 | MMP8 791/4885SLC6A4 3835/4885ACACB 892/4885 |
| US-20030087843-A1 | O-pyrazole glucoside SGLT2 inhibitors and method of use | SLC5A2, SLC5A1, SLC2A1 | MMP8 4196/4885SLC6A4 155/4885ACACB 1430/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.